Pacira BioSciences(NASDAQ) PCRX

Pacira BioSciences, Inc. NASDAQ:PCRX helps doctors treat pain without addictive narcotics. It makes injections providing relief after surgical procedures. These products help patients recover safely without using opioids.

Managing Pain Without Opioids

• EXPAREL: Long-acting local anesthetic injected during surgery to provide pain relief for several days after a procedure.
• ZILRETTA: Extended-release corticosteroid injection designed to manage knee pain for patients suffering from osteoarthritis.
• PCRX-201: Experimental gene therapy currently in testing that aims to provide long-term joint pain relief with one injection.
• PCRX-2002: Investigational long-acting pain medication being developed for use following surgical operations.

Strategic Moves and New Partners

• Divested the iovera device business to Zimmer in July 2026 for an upfront payment of $70.0 million.
• Entered a partnership with LG Chem in January 2026 to expand the availability of EXPAREL in Asian-Pacific markets.
• Expanded patient access in July 2026 through a new reimbursement agreement with UnitedHealthcare for outpatient settings.
• Completed a manufacturing upgrade in July 2026 to produce its lead gene therapy candidate at a commercial scale.

Innovation in Drug Delivery

Pacira uses a proprietary delivery technology that wraps medicine in tiny particles to release it slowly over several days. This allows a single injection to provide long-lasting relief directly at the site of surgery or injury.

A Closer Look at the Finances

• Total revenues reached $192.4 million in the three-month period ended June 30, 2026, which was a 6% increase year over year.
• EXPAREL net product sales grew 3% year over year to $147.8 million during the three-month period ended June 30, 2026.
• ZILRETTA net product sales rose 4% year over year to $32.6 million in the three-month period ended June 30, 2026.
• The company held $251.0 million in cash, cash equivalents, and available-for-sale investments as of June 30, 2026.

The Evolving Business Model

Pacira has shifted its focus toward becoming a biopharmaceutical company centered on non-opioid pain therapies and genetic medicines. Its recent sale of medical device assets and investment in gene therapy manufacturing support this long-term strategy.